Federal Appeals Court Reaffirms That 23andMe Won’t Face Class Action Suit
The appellate court panel said the allegations that the genetic testing company misled consumers belong in arbitration. Also in the news, some tech workers in Silicon Valley are using nootropic "smart pills" to give them an edge.
23andMe Escapes California Class Action For Arbitration
A federal appeals court ruled Tuesday that genetic testing company 23andMe can't be sued over allegations that it misled customers about its test kit because the claims belong in arbitration. A unanimous panel at the 9th U.S. Circuit Court of Appeals in San Francisco affirmed a lower court's decision the class-action claims belonged in arbitration thanks to 23andMe's terms of service agreement. The plaintiffs sued back in 2013 alleging the Silicon Valley startup lied about its DNA test kit's health benefits, breached its warranty and used unfair business practices. (Teichert, 8/24)
Nootropics, Biohacking And Silicon Valley’s Pursuit Of Productivity
Nootropics are trending right now. A crop of new companies are selling these so-called productivity or smart pills. The major customer base is a community of “biohackers” in Silicon Valley who hope nootropics will give them an edge in work and life. (Harnett, 8/24)